Formulation Development and Evaluation of Drug Loaded Microsponges of Sulindac Sodium

Palanisamy Pethappachetty^{1,*}, Rajappa Margret Chandira¹, Karthir Kumaresan², Dominic Antony samy³

¹Department of Pharmaceutics, Vinayaka Mission's College of Pharmacy, Vinayaka Mission's Research Foundation (Deemed to be University), Salem, Tamil Nadu, INDIA.

²Vinayaka Mission's College of Pharmacy, Vinayaka Mission's Research Foundation (Deemed to be University), Salem, Tamil Nadu (State), INDIA.

³Sona College of Technology, Salem, Tamil Nadu, INDIA.

Submission Date: 20-05-2022; Revision Date: 19-06-2022; Accepted Date: 15-07-2022.

ABSTRACT

This research work aimed to develop and evaluate the microsponge formulations for Sulindac sodium. Sulindac sodium a poorly water-soluble drug with high first-pass metabolism is available only as conventional tablets. Thus, an attempt was made to formulate a drug-loaded microsponge to eliminate the first-pass metabolism and also improve the bio-availability of the drug. This work aimed to prepare a stable microsponge formulation of sulindac sodium for the enhancement of bioavailability and reducing the dose frequency. The quasi emulsion solvent diffusion approach was used to create the microsponges. The percentage yield, drug load efficiency, morphological analysis, in vitro drug release and stability studies were evaluated. Based on the result selected for the optimized formulation SM5, the morphology of the optimized formulation was by scanned electron microscopy which was found to be uniform and containing pores without any crystals. The formulation SM5 was found to be in an optimized formulation which shows 92.05% release at 12 hr. Stability studies showed that indicated negligible levels of changes were observed in load efficiency, morphological analysis and in vitro release, indicating the susceptibility to stability problems during storage at room temperature and 40°C/75%RH was observed after 3 months. On the basis of the findings, drug-loaded microsponges show improvised release behaviour and provide an effective modified route of administration.

Correspondence: Prof. Dr. Palanisamy Pethappachetty, Department of Pharmaceutics, Vinayaka Mission's College of Pharmacy, Vinayaka Mission's Research Foundation (Deemed to be University), Salem-636308, Tamil Nadu, INDIA.

Email: palanisamy2907@ gmail.com

Keywords: Microsponge, Solubility, Porous polymeric system, Sulindac sodium, morphological analysis and *in vitro* drug release.

INTRODUCTION

Oral administration of medicines is the most common and convenient method of medication administration, resulting in the highest level of patient compliance. The core of pharmaceutical research is the development of orally effective new medications and technology. Oral administration is considerably more successful for medications with high solubility and gastrointestinal permeability, and the creation of pharmaceuticals

SCAN QR CODE TO VIEW ONLINE			
	www.ajbls.com		
	DOI: 10.5530/ajbls.2022.11.57		

with low aqueous solubility or high difficulty is much more difficult.^[1] Even before a medicine reaches systemic circulation, its first-pass metabolism in the GI tract and liver may result in lower bioavailability. To boost the effectiveness of active substances while improving product safety, a novel approach is needed, and microsponges polymeric delivery system might be employed to tackle the challenges.^[2]

The Microsponge polymeric system consists of microscopic sponge-like (porous) spherical particles that may entrap active substances and release them into the systemic circulation over time in response to a trigger. They may also increase the product's visual features and prolong the product's stability due to their unique arrangement.^[3] Microsponges also speed up the solubilization of weakly water-soluble medications

by trapping them in the microsponges' small pores. Because these pores are so small, the drug is effectively reduced to microscopic particles, increasing surface area and solubilization rate significantly.^[4]

Sulindac sodium is a nonsteroidal anti-inflammatory medicine (NSAID) that is primarily used to treat rheumatoid arthritis. It is a poorly water-soluble drug with a high first-pass metabolism and is only accessible in the form of traditional tablets. It has anti-inflammatory properties because it inhibits both COX-1 and COX-2, which inhibits prostaglandin formation.^[5]

This work aimed to prepare a stable microsponge formulation of sulindac sodium for the enhancement of bioavailability and reduced dose frequency.

MATERIALS AND METHODS

The following materials available were supplied by the manufacturer, Sulindac Sodium (Tokyo Chemical Industry), Eutragit and Trierthyl Citrate (a free gift sample from KMS Health Centre, Chennai), Polyvinyl Alcohol, Ethanol

Preparation of microsponges^[6-8]

Porous microsponges were also made using a quasiemulsion solvent diffusion process utilising an interior phase containing a polymer such as Eudragit dissolved in ethanol. The medication is then progressively added to the polymeric solution and dissolved at 35°C using ultrasonication, with a plasticiser such triethyl citrate (TEC) added to increase plasticity. As a result, the inner phase is transferred to the external phase, which comprises polyvinyl alcohol and distilled water, and constantly agitated for 1 hr. After that, the microsponges were isolated from the mixture by filtering it. In an airheated oven at 40°C, the product was cleaned and dried for 12 hr. The preparation procedure is shown in the Table 1.

Evaluation Studies of Microsponges Preformulation studies

UV-VIS spectrophotometer evaluation^[9]

A Shimadzu spectrophotometer was used to gather ultraviolet and visible spectra (UV–Vis) in the 200–800 nm range, and a 2.5 X 10-5 mol L-1 ethanolic solution was created for this research.

Standard Calibration Graph of Sulindac sodium^[10]

In a volumetric flask (100 ml), a weighed quantity of medication (100 mg) was dissolved in a little amount of ethanol. Finally, ethanol (Stock I, 1000mg/ml) was used to get the volume up to the required level. Stock II was

Table 1: Formulation of Microsponges.						
Ingredients	SM1	SM2	SM3	SM4	SM5	
Inner phase						
Sulindac sodium (mg)	100	100	100	100	100	
Eudragit (mg)	100	80	60	40	20	
Ethanol (ml)	10	10	10	10	10	
Outer phase						
PVA (mg)	50	50	50	50	50	
Water (ml)	200	200	200	200	200	

Table 2: Concentration vs Absorbance.				
SI/no	Concentration	Absorbance		
1.	0	0.0000		
2.	1	0.1525		
3.	2	0.2268		
4.	3	0.3362		
5.	4	0.4216		
6.	5	0.5037		
7.	6	0.5922		
8.	7	0.7297		
9.	8	0.7815		
10.	9	0.8395		
11.	10	0.8917		



Figure 1: UV spectrum of pure drug.

created by mixing 10ml of main stock with 100ml of volumetric flask and adjusting the volume to the mark (Stock II 100g/ml). Stock III was created by mixing 10ml of main stock with 100ml of volumetric flask and adjusting the volume to the mark (Stock III 10g/ml). Different concentrations of solutions (i.e. 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10g/ml for ethanol) were produced from the aforesaid stock solutions and analysed using a UV-visible spectrophotometer at 202 nm. The preparation procedure is shown in Table 2 and Figures 1-2.



Figure 2: Calibration curves of pure drug.



Figure 3: IR spectrum of Sulindac sodium.

Compatibility studies^[11]

The IR spectrum of pure drug, a physical combination of drug and excipients, and formed microsponge were taken in an ATR-FTIR spectrometry sample holder and studied for any presence in compatibility produce. The preparation procedure is shown in the Figure 3-4.

Production yield^[12]

It is calculated to determine the efficacy of any methodology, assisting in the selection of the best production method. The Practical yield was calculated by dividing the number of microsponges recovered from each preparation by the total amount of starting material after the formulations were prepared (Theoretical yield). The formula below may be used to compute it. The preparation procedure is shown in the Table 3.

$$Production yield = \frac{Practical yield}{Theoretical yield (drug + polymer)} \times 100$$

Drug load efficiency^[13]

100 mg of the prepared microscope were dissolved in ethanol in an a100ml volumetric flask and made up to the mark after the proper dilution absorbance of the drug was measured with a UV spectrometer at 202 nm.



Figure 4: IR spectrum of physical mixtures of drug and excipients.

Determination Percentage yield and Drug load efficiency

Table 3: Percentage yield and Drug load efficiency.					
Formulation code	Percentage yield	Drug load efficiency			
SM1	77.84	75.5			
SM2	81.11	77.9			
SM3	84.43	80.3			
SM4	87.85	83.8			
SM5	91.66	85.6			

the following calculation can be used to calculate the load efficiency of the drug. The preparation procedure is shown in the Table 3.

$$load efficiency = \frac{load drug content}{load drug content} \times heo$$

Morphology determination by scanning electron microscopy (SEM)^[14]

The Morphology of the prepared microsponges was determined using scanning electron microscopy. The SEM may be used to characterize the shape and size of microscopic objects in relation to particle size. An electron beam was used to scan the material in a regulated pattern in an evacuated chamber. The SEM images of optimized drug-loaded microsponge formulation (SM5) and pure drug were scanned at various magnifications of 250X, 20.00 K X, and 30.00 K X. The preparation procedure is shown in Figure 5.

In vitro drug release^[15-16]

In vitro experiments were performed by dialysis method with a compartment capacity of 900 mL and a cellophane membrane. The prepared microsponge was kept across the membrane, and the diffusion cell's compartment

SEM Analysis



Figure 5: SEM analysis of prepared microsponge.

Table 4: In vitro drug release of microsponge.						
Formulation Code	SM1	SM2	SM3	SM4	SM5	
Time in hrs		% Cumulative Drug Release				
0	0	0	0	0	0	
0.5	11.43	15.94	19.51	21.74	24.84	
1	19.85	23.18	28.13	35.06	37.96	
3	27.06	29.98	33.63	47.38	49.95	
5	34.59	38.82	46.06	52.82	62.50	
7	48.79	51.14	55.03	61.10	76.29	
9	55.97	62.69	68.98	75.84	84.62	
12	62.10	66.46	74.37	81.22	92.05	

was filled with pH 5.5 acetate. The whole thing was held together by a magnetic stirrer. The solution in the receptor compartment was continually swirled at 50 rpm with a magnetic bead, and the temperature was maintained at 32°C. The samples were taken at various intervals up to 12 hr and examined for a percentage of drug release from the microsponge by using a UV spectrophotometer at 202nm. The preparation procedure is shown in the Table 4 and Figure 6.

Determination of short-time stability studies for microsponges^[17-18]

The optimized formulation of microsponge for the stability determination accelerated stability conditions at (40°C/75%RH). It's taken and examined for load efficiency and *in-vitro* drug release studied every 30 days



Figure 6: Graph of in-vitro Drug Release.

Stability Study for the Optimized SM5 Formulation

Table 5: Stability Parameter of theoptimized formulation.				
Parameters	Initial	After one month 40/75 (°C/ RH)	After the second month 40/75 (°C/ RH)	After the third month 40/75 (°C/ RH)
Load efficiency%	85.6	85.2	84.7	83.9
<i>In vitro</i> drug release	92.05	91.67	90.85	90.15

for a period of 3 months. All of these factors are compared to the initial sample and evaluated to see whether it meets the specifications. If it does, the batch passes the test. The preparation procedure is shown in the Table 5.

RESULTS AND DISCUSSION

Pre-formulation studies^[19]

UV-VIS spectrophotometer evaluation

UV spectrophotometric analysis the maximum absorbance of the drug was found to be 202nm and good linearity with R^2 value of 0.989, which suggests that it obeys the Beer-Lamberts law.

Compatibility studies by ATR-FTIR

The complete principal drug peaks were seen at 1793.38 (C=O stretching), 1693.58 (C-C stretching), 1462.44 (C-H stretching), 14075 (S=O stretching), 1187.90, 1264.60 (C-F stretching) during ATR-FTIR tests to determine the physicochemical interaction between drug and excipients employed in microsponge. Sulindac peaks were identified in the spectra of the SM5 formulation. These findings revealed that no chemical interactions occurred throughout the microsponge production process.

SEM Analysis

SEM analysis was studied for the optimized drugloaded microsponge formulation (SM5) and the pure drug was evaluated for the surface morphology of the formulations at magnifications of 250X, 20.00 K X, and 30.00 K X. These images revealed that the prepared microscope was finely spherical and homogenous, with no detectable drug material.

Determination Percentage yield and Drug load efficiency^[20]

The percentage yield, Load efficiency of sulindac microsponge showed percentage yield ranging from 77.84 to 91.66% and drug load efficiency 75.5 to 85.6 mg respectively, From the result, increasing drug-polymer concentration increase the percentage yield and load efficiency of microsponge.

In vitro Drug Release^[21]

From the above result, the *in vitro* release studies of gel from an optimized formulation of SM5 microsponge were performed on the formulations SMG1to SMG4. 91.22% of drug release from SMG4 formulation was observed after a time period of 12 hrs and compared with the release of pure drug. In comparison, SMG4 formulation exhibited reasonably, easily spreadable and good texture with the release of the drug, hence it was considered the optimized formulation.

Stability Study for the Optimized SM5 Formulation

The improved formulation was subjected to a 3-month stability assessment at 40°C/75 % RH, as per ICH guidelines. The findings revealed that there was no significant change in the physical and chemical parameters of the microsponge at the end of the third month, indicating that the formulation (SM5) was stable.

SUMMARY AND CONCLUSION

Based on the results of the studies, it is concluded that the Sulindac-loaded microsponge formulation especially SM5 microsponge formulation exhibited improvised release behaviour, which would help in minimizing the dose frequency, improvise the patient compliance and provide an effective modified route of administration.

ACKNOWLEDGEMENT

The authors are thankful to Dr. B.Jaykar, Professor and Registrar, Vinayaka Mission's Research Foundation (Deemed to be University) and Vinayaka Mission's College of Pharmacy, Salem, Tamil Nadu for extending their support and facilities for this research.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

ABBREVIATIONS

ATR-FTIR: Attenated Total Reflectance- Fourier Transform Infrared; **COX:** Cyclo Oxygenase; **Nm:** Nanometer; **PVA:** Poly Vinyl Alcohol; **SM1:** Sulindac Microsponge 1.

REFERENCES

- Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm. 2009 Mar 1;71(3):505-18. doi: 10.1016/j.ejpb.2008.09.028, PMID 18984051.
- Gupta S, Kesarla R, Omri A. Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems. ISRN Pharm. 2013;2013:848043. doi: 10.1155/2013/848043, PMID 24459591.
- Chadawar V, Shaji J. Microsponge delivery system. Curr Drug Deliv. 2007 Apr 1;4(2):123-9. doi: 10.2174/156720107780362320, PMID 17456031.
- Jelvehgari M, Siahi-Shadbad MR, Azarmi S, Martin GP, Nokhodchi A. The microsponge delivery system of benzoyl peroxide: Preparation, characterization and release studies. Int J Pharm. 2006 Feb 3;308(1-2):124-32. doi: 10.1016/j.ijpharm.2005.11.001, PMID 16359833.
- Harima Y, Maekawa T, Miyauchi Y, Tsutsui T, Sakabe T, Koshiro A. Intoxication with sulindac, tiaramide hydrochloride and diclofenac sodium. Intensive Care Med. 1987 Jul;13(5):361-2. doi: 10.1007/BF00255796, PMID 3655104.
- Comoglu T, Gönül N, Baykara T. The effects of pressure and direct compression on tabletting of microsponges. Int J Pharm. 2002 Aug 21;242(1-2): 191-5. doi: 10.1016/s0378-5173(02)00155-2, PMID 12176245.
- Vemula SK, Veerareddy PR. Different approaches to design and evaluation of colon specific drug delivery systems. Int J Pharm Technol. 2009 Dec;1(1):1-35.
- Cui F, Yang M, Jiang Y, Cun D, Lin W, Fan Y et al. Design of sustainedrelease nitrendipine microspheres having solid dispersion structure by quasi-emulsion solvent diffusion method. J Control Release. 2003 Sep 4;91(3):375-84. doi: 10.1016/s0168-3659(03)00275-x, PMID 12932715.
- Yegin BA, Moulari B, Durlu-Kandilci NT, Korkusuz P, Pellequer Y, Lamprecht A. Sulindac loaded alginate beads for a mucoprotective and controlled drug release. J Microencapsul. 2007 Jan 1;24(4):371-82. doi: 10.1080/02652040701298153, PMID 17497390.
- Altinöz S, Tekeli D. Analysis of glimepiride by using derivative UV spectrophotometric method. J Pharm Biomed Anal. 2001 Jan 1;24(3):507-15. doi: 10.1016/s0731-7085(00)00445-3, PMID 11199230.
- Patel P, Ahir K, Patel V, Manani L, Patel C. Drug-Excipient compatibility studies: first step for dosage form development. J Pharm Innov. 2015 Jul 1;4;5(A):14.
- Salonen J, Laitinen L, Kaukonen AM, Tuura J, Björkqvist M, Heikkilä T *et al.* Mesoporous silicon microparticles for oral drug delivery: loading and release of five model drugs. J Control Release. 2005 Nov 28;108(2-3):362-74. doi: 10.1016/j.jconrel.2005.08.017, PMID 16169628.
- Zucker D, Marcus D, Barenholz Y, Goldblum A. Liposome drugs' loading efficiency: A working model based on loading conditions and drug's physicochemical properties. J Control Release. 2009 Oct 1;139(1):73-80. doi: 10.1016/j.jconrel.2009.05.036, PMID 19508880.
- Annaz B, Hing KA, Kayser M, Buckland T, Di Silvio LD. Porosity variation in hydroxyapatite and osteoblast morphology: A scanning electron microscopy study. J Microsc. 2004 Jul;215(1):100-10. doi: 10.1111/j.0022-2720.2004.01354.x, PMID 15230881.
- D'Souza SS, DeLuca PP. Development of a dialysis *in vitro* release method for biodegradable microspheres. AAPS PharmSciTech. 2005 Jun;6(2):E323-8. doi: 10.1208/pt060242, PMID 16353991.
- Goren MG, Navon-Venezia S, Chmelnitsky I, Carmeli Y. Carbapenem-Resistant KPC-2-Producing Escherichia coli in a Tel Aviv Medical Center,

2005 to 2008. Antimicrob Agents Chemother. 2010;54(6):2687-91. doi: 10.1128/AAC.01359-09.

- Aashigari S, Goud R, Sneha S, Vykuntam U, Potnuri NR. Stability studies of pharmaceutical products. World J Pharm Res. 2018 Oct 25;8:479-92.
- Bajaj S, Singla D, Sakhuja N. Stability testing of pharmaceutical products. J Appl Pharm Sci. 1930 Jan 11(Issue):129-38.
- Swetha A, Gopal Rao M, Venkata Ramana K, Niyaz Basha B, Koti Reddy V. Formulation and *in-vitro* evaluation of etodolac entrapped in microsponge based drug delivery system. Int J Pharm. 2011;1(2):73-80.
- D'souza JI, More HN. Topical anti-inflammatory gels of fluocinolone acetonide entrapped in eudragit based microsponge delivery system. Res J Pharm Technol. 2008;1(4):502-6.
- Comoğlu T, Gönül N, Baykara T. Preparation and *in vitro* evaluation of modified release ketoprofen microsponges. farmaco. 2003 Feb 1;58(2):101-6. doi: 10.1016/s0014-827x(02)00007-1, PMID 12581775.

Cite this article: Pethappachetty P, Chandira RM, Kumaresan K, Samy DA. Formulation Development and Evaluation of Drug Loaded Microsponges of Sulindac Sodium. Asian J Biol Life Sci. 2022;11(2):423-8.